Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2023.2203812
Abstract: BACKGROUND Biosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhancements, support services, and removal of painful excipients to capture market share. Prescribers, however, are often unaware of… read more here.
Keywords: originator versus; adalimumab biosimilars; versus adalimumab; adalimumab ... See more keywords